Victory is seeking to acquire, license and develop therapeutics in pain and related healthcare segments.  Primarily, Victory targets acquisition of currently marketed products for promotion through our sales force. Simultaneously, Victory is developing a therapeutics pipeline focused on pain and related conditions. These development programs will be NDA approvals under FDA 505(b)(2) regulations for new product combinations, formulations and improved methods of delivery of currently marketed molecules. Victory’s product development strategy significantly reduces development time, cost, and risk.  The company’s products will be commercialized to our customer base through our U.S. national sales organization. Outside the U.S., the company will seek to maximize its assets through partnerships.